JP2021529172A5 - - Google Patents
Info
- Publication number
- JP2021529172A5 JP2021529172A5 JP2020570902A JP2020570902A JP2021529172A5 JP 2021529172 A5 JP2021529172 A5 JP 2021529172A5 JP 2020570902 A JP2020570902 A JP 2020570902A JP 2020570902 A JP2020570902 A JP 2020570902A JP 2021529172 A5 JP2021529172 A5 JP 2021529172A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- prodrug
- alkyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688225P | 2018-06-21 | 2018-06-21 | |
| US62/688,225 | 2018-06-21 | ||
| US201962827505P | 2019-04-01 | 2019-04-01 | |
| US62/827,505 | 2019-04-01 | ||
| PCT/US2019/038245 WO2019246403A1 (en) | 2018-06-21 | 2019-06-20 | Ectonucleotidase inhibitors and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021529172A JP2021529172A (ja) | 2021-10-28 |
| JP2021529172A5 true JP2021529172A5 (enExample) | 2022-05-16 |
| JP7538047B2 JP7538047B2 (ja) | 2024-08-21 |
Family
ID=68981317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570902A Active JP7538047B2 (ja) | 2018-06-21 | 2019-06-20 | エクトヌクレオチダーゼ阻害剤及びその使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11078228B2 (enExample) |
| EP (1) | EP3810617A4 (enExample) |
| JP (1) | JP7538047B2 (enExample) |
| KR (1) | KR102902754B1 (enExample) |
| CN (1) | CN112888696B (enExample) |
| AU (1) | AU2019288495B2 (enExample) |
| BR (1) | BR112020025132B1 (enExample) |
| CA (1) | CA3104088A1 (enExample) |
| CL (1) | CL2020003339A1 (enExample) |
| CO (1) | CO2021000049A2 (enExample) |
| IL (1) | IL279475B2 (enExample) |
| MX (1) | MX2020013320A (enExample) |
| PH (1) | PH12020552214A1 (enExample) |
| SG (1) | SG11202012001YA (enExample) |
| TW (1) | TWI911140B (enExample) |
| WO (1) | WO2019246403A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102638592B1 (ko) * | 2016-12-22 | 2024-02-19 | 안텐진 테라퓨틱스 리미티드 | 엑토뉴클레오티다제 억제제 및 이의 용도 |
| WO2018208980A1 (en) | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| IL304348B2 (en) | 2018-04-30 | 2024-08-01 | Oric Pharmaceuticals Inc | CD73 inhibitors |
| SG11202012001YA (en) * | 2018-06-21 | 2021-01-28 | Calithera Biosciences Inc | Ectonucleotidase inhibitors and methods of use thereof |
| TWI821559B (zh) * | 2019-04-28 | 2023-11-11 | 大陸商上海和譽生物醫藥科技有限公司 | 一種cd73抑制劑，其製備方法和應用 |
| WO2020257429A1 (en) * | 2019-06-20 | 2020-12-24 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
| JP7557522B2 (ja) | 2019-07-16 | 2024-09-27 | オリック ファーマシューティカルズ，インク． | Ｃｄ７３阻害剤 |
| PL4051688T3 (pl) | 2019-10-30 | 2025-09-22 | Oric Pharmaceuticals, Inc. | Inhibitory cd73 |
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| CN116375772B (zh) * | 2023-02-13 | 2024-11-01 | 北京先通国际医药科技股份有限公司 | 腺苷的制备方法及其用途 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR960008669B1 (ko) | 1991-04-24 | 1996-06-28 | 야마사 쇼오유 가부시끼가이샤 | 1-β-D-아라비노푸라노실-(E)-5-(2-할로게노비닐) 우라실 유도체 |
| AU5449094A (en) | 1992-11-02 | 1994-05-24 | Affymax Technologies N.V. | Novel photoreactive protecting groups |
| US5635608A (en) | 1994-11-08 | 1997-06-03 | Molecular Probes, Inc. | α-carboxy caged compounds |
| TW528755B (en) | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
| NL1005244C2 (nl) | 1997-02-10 | 1998-08-18 | Inst Voor Agrotech Onderzoek | Oppervlakte-actieve aminen en glycosiden. |
| WO2004096233A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates |
| EP1860113A1 (en) | 2006-05-24 | 2007-11-28 | Rheinische Friedrich-Wilhelms-Universität Bonn | Ectonucleotidase inhibitors |
| WO2008011406A2 (en) * | 2006-07-18 | 2008-01-24 | Anadys Pharmaceuticals, Inc. | Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines |
| JP2011503084A (ja) | 2007-11-07 | 2011-01-27 | シェーリング コーポレイション | 新規の細胞周期チェックポイント調節剤およびこれらの調節剤とチェックポイント阻害剤との併用 |
| EP2070938A1 (en) * | 2007-12-13 | 2009-06-17 | Heidelberg Pharma AG | Clofarabine dietherphospholipid derivatives |
| CA2684017A1 (en) | 2009-10-22 | 2011-04-22 | Universite Laval | Ectonucleotidase pyrophosphate/phosphodiesterase-1 (enpp-1) as a target for the treatment of aortic valve stenosis and cardiovascular calcification |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| WO2012006351A1 (en) | 2010-07-08 | 2012-01-12 | Life Technologies Corporation | In situ chemiluminescent substrates and assays |
| CN102311472B (zh) | 2010-07-09 | 2014-09-03 | 神隆(昆山)生化科技有限公司 | 2-氯-9-(2’-脱氧-2’-氟-β-D-阿拉伯呋喃糖基)-腺嘌呤的制备 |
| JP2014516947A (ja) | 2011-05-03 | 2014-07-17 | ライフ テクノロジーズ コーポレーション | フラッシュ・グロー型の１，２−ジオキセタン |
| US8883800B2 (en) * | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| GB201220843D0 (en) | 2012-11-20 | 2013-01-02 | Univ College Cork Nat Univ Ie | Compound |
| MA39986A (fr) | 2014-04-25 | 2017-03-01 | Vitae Pharmaceuticals Inc | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer |
| US10068577B2 (en) * | 2014-04-25 | 2018-09-04 | Dolby Laboratories Licensing Corporation | Audio segmentation based on spatial metadata |
| WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
| SI3362461T1 (sl) | 2015-10-16 | 2022-05-31 | Modernatx, Inc. | Analogi kape MRNA z modificirano fosfatno povezavo |
| WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
| US10611790B2 (en) | 2015-11-02 | 2020-04-07 | Mitobridge, Inc. | Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases |
| CN107849084B (zh) * | 2015-12-03 | 2021-09-14 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为sting调节剂的环状嘌呤二核苷酸 |
| EP3510040A4 (en) * | 2016-09-09 | 2020-06-03 | Calithera Biosciences, Inc. | EKTONUCLEOTIDASE INHIBITORS AND METHOD FOR USE THEREOF |
| US10794113B2 (en) * | 2016-12-22 | 2020-10-06 | Marketing Displays, Inc. | Compact privacy screen |
| KR102638592B1 (ko) * | 2016-12-22 | 2024-02-19 | 안텐진 테라퓨틱스 리미티드 | 엑토뉴클레오티다제 억제제 및 이의 용도 |
| WO2018208727A1 (en) * | 2017-05-08 | 2018-11-15 | Eternity Bioscience Inc. | Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof |
| WO2018208980A1 (en) | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| CN109503587B (zh) * | 2017-09-14 | 2022-01-11 | 辽宁利锋科技开发有限公司 | 双杂环三氮唑核苷类似物的抗肿瘤作用与应用 |
| US11377469B2 (en) * | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| IL304348B2 (en) * | 2018-04-30 | 2024-08-01 | Oric Pharmaceuticals Inc | CD73 inhibitors |
| WO2019232319A1 (en) * | 2018-05-31 | 2019-12-05 | Peloton Therapeutics, Inc. | Compositions and methods for inhibiting cd73 |
| SG11202012001YA (en) | 2018-06-21 | 2021-01-28 | Calithera Biosciences Inc | Ectonucleotidase inhibitors and methods of use thereof |
| WO2020257429A1 (en) | 2019-06-20 | 2020-12-24 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
-
2019
- 2019-06-20 SG SG11202012001YA patent/SG11202012001YA/en unknown
- 2019-06-20 MX MX2020013320A patent/MX2020013320A/es unknown
- 2019-06-20 WO PCT/US2019/038245 patent/WO2019246403A1/en not_active Ceased
- 2019-06-20 CN CN201980054369.1A patent/CN112888696B/zh active Active
- 2019-06-20 KR KR1020217001701A patent/KR102902754B1/ko active Active
- 2019-06-20 IL IL279475A patent/IL279475B2/en unknown
- 2019-06-20 JP JP2020570902A patent/JP7538047B2/ja active Active
- 2019-06-20 EP EP19823042.7A patent/EP3810617A4/en active Pending
- 2019-06-20 US US16/447,159 patent/US11078228B2/en active Active
- 2019-06-20 AU AU2019288495A patent/AU2019288495B2/en active Active
- 2019-06-20 BR BR112020025132-1A patent/BR112020025132B1/pt active IP Right Grant
- 2019-06-20 CA CA3104088A patent/CA3104088A1/en active Pending
- 2019-06-21 TW TW108121817A patent/TWI911140B/zh active
-
2020
- 2020-12-18 PH PH12020552214A patent/PH12020552214A1/en unknown
- 2020-12-21 CL CL2020003339A patent/CL2020003339A1/es unknown
-
2021
- 2021-01-06 CO CONC2021/0000049A patent/CO2021000049A2/es unknown
- 2021-06-28 US US17/359,990 patent/US11858957B2/en active Active
-
2023
- 2023-11-01 US US18/499,248 patent/US12421273B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021529172A5 (enExample) | ||
| JP2022537358A5 (enExample) | ||
| JP2024531477A5 (enExample) | ||
| JP6523303B2 (ja) | Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物 | |
| AU2015207757B2 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | |
| HRP20210848T1 (hr) | Sastavi i postupci za sprječavanje aktivnosti arginaze | |
| JP2019530669A5 (enExample) | ||
| WO2018051254A1 (en) | Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators | |
| WO2018051255A1 (en) | Cyclic substituted-1,3,4-oxadiazole and thiadiazole compounds as immunomodulators | |
| JP2020504735A5 (enExample) | ||
| EA036446B1 (ru) | Соединения и композиции для подавления активности shp2 | |
| JP2017515802A5 (enExample) | ||
| JP2016502544A5 (enExample) | ||
| JP2019524852A5 (enExample) | ||
| RU2015116102A (ru) | Гетероароматические соединения-модуляторы фосфоинозидит-3-киназы и способы применения | |
| CA2992960A1 (en) | Fused imidazoles as midh1 inhibitors | |
| JP2018529780A5 (enExample) | ||
| CA2992364A1 (en) | 5-hydroxyalkylbenzimidazoles as midh1 inhibitors | |
| JP2015536994A5 (enExample) | ||
| RU2015131467A (ru) | Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы | |
| JP2022507025A5 (enExample) | ||
| US20220411438A1 (en) | Inhibitors of Tryptophan Dioxygenases (IDO1 and TDO) And Their Use In Therapy | |
| CA2988356A1 (en) | N-menthylbenzimidazoles as midh1 inhibitors | |
| JP2017502967A5 (enExample) | ||
| CA2965201A1 (en) | Benzimidazol-2-amines as midh1 inhibitors |